This site is intended for healthcare professionals

Direct-acting oral anticoagulants (DOACs): bleeding risk and reversal agents

Posted 10 Sept 2020

Dr Julie Oliver

Dr Julie Oliver discusses this topic in the context of a recent update from the Medicines and Healthcare products Regulatory Agency (MHRA).

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page